» Articles » PMID: 35459096

Hyperuricemia and Diabetes Mellitus when Occurred Together Have Higher Risks Than Alone on All-cause Mortality and End-stage Renal Disease in Patients with Chronic Kidney Disease

Overview
Journal BMC Nephrol
Publisher Biomed Central
Specialty Nephrology
Date 2022 Apr 23
PMID 35459096
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Hyperuricemia and diabetes mellitus (DM) are associated with increased mortality risk in patients with chronic kidney disease (CKD). Here we aimed to evaluate the independent and joint risks of these two conditions on mortality and end stage kidney disease (ESKD) in CKD-patients.

Methods: This retrospective cohort study enrolled 4380 outpatients (with CKD stage 3-5) with mortality and ESKD linkage during a 7-year period (from 2007 to 2013). All-causes mortality and ESKD risks were analyzed by multivariable-adjusted Cox proportional hazards models (adjusted for age, sex, smoke, previous coronary arterial disease, blood pressure, and medications for hyperlipidemia, hyperuricemia and renin-angiotensin system inhibitors).

Results: Overall, 40.5% of participants had DM and 66.4% had hyperuricemia. In total, 356 deaths and 932 ESKD events occurred during the 7 years follow-up. With the multivariate analysis, increased risks for all-cause mortality were: hyperuricemia alone, HR = 1.48 (1-2.19); DM alone, and HR = 1.52 (1.02-2.46); DM and hyperuricemia together, HR = 2.12 (1.41-3.19). Similar risks for ESKD were: hyperuricemia alone, HR = 1.34 (1.03-1.73); DM alone, HR = 1.59 (1.15-2.2); DM and hyperuricemia together, HR = 2.46 (1.87-3.22).

Conclusions: DM and hyperuricemia are strongly associated with higher all-cause mortality and ESKD risk in patients with CKD stage 3-5. Hyperuricemia is similar to DM in terms of risk for all-cause mortality and ESKD. DM and hyperuricemia when occurred together further increase both risks of all-cause mortality and ESKD.

Citing Articles

Systemic immune inflammation index and all-cause mortality in chronic kidney disease: A prospective cohort study.

Jia M, Yuan W, Chen Y, Wang Y, Shang L, Han S Immun Inflamm Dis. 2024; 12(9):e1358.

PMID: 39254488 PMC: 11386342. DOI: 10.1002/iid3.1358.


Correlation of uric acid with microalbuminuria in Type-2 diabetic patients with normal creatinine.

Zeb S, Babar B, Bibi S, Shah M Pak J Med Sci. 2024; 40(5):951-955.

PMID: 38827879 PMC: 11140356. DOI: 10.12669/pjms.40.5.8208.


Interaction between anemia and hyperuricemia in the risk of all-cause mortality in patients with chronic kidney disease.

Lu Z, Lu F, Zhang R, Guo S Front Endocrinol (Lausanne). 2024; 15:1286206.

PMID: 38586465 PMC: 10998448. DOI: 10.3389/fendo.2024.1286206.


Evaluating the risk of developing hyperuricemia in patients with type 2 diabetes mellitus using least absolute shrinkage and selection operator regression and machine learning algorithm.

Chen Q, Hu H, He Q, Huang X, Shi H, Cao X Digit Health. 2024; 10:20552076241241381.

PMID: 38550266 PMC: 10976486. DOI: 10.1177/20552076241241381.

References
1.
Valle M, Martos R, Canete M, Valle R, van Donkelaar E, Bermudo F . Association of serum uric acid levels to inflammation biomarkers and endothelial dysfunction in obese prepubertal children. Pediatr Diabetes. 2014; 16(6):441-7. DOI: 10.1111/pedi.12199. View

2.
Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

3.
Mazzali M, Hughes J, Kim Y, Jefferson J, Kang D, Gordon K . Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001; 38(5):1101-6. DOI: 10.1161/hy1101.092839. View

4.
Yang C, Shin D, Jo E . The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases. Int Neurourol J. 2012; 16(1):2-12. PMC: 3321399. DOI: 10.5213/inj.2012.16.1.2. View

5.
Chao H, Liu J, Lin J, Chen C, Wu C, Cheng T . Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin. 2008; 29(11):1301-12. DOI: 10.1111/j.1745-7254.2008.00877.x. View